Standard BioTools (LAB) Financials

$1.06 +0.03 (+2.43%)

As of 10:32 AM Eastern

Annual Income Statements for Standard BioTools

This table shows Standard BioTools' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021
Net Income / (Loss) Attributable to Common Shareholders	-185	-75	-190	-59
Consolidated Net Income / (Loss)	-139	-75	-190	-59
Net Income / (Loss) Continuing Operations	-139	-75	-190	-59
Total Pre-Tax Income	-138	-74	-193	-64
Total Operating Income	-175	-77	-116	-67
Total Gross Profit	84	50	37	69
Total Revenue	174	106	98	131
Operating Revenue	174	106	98	131
Total Cost of Revenue	90	56	61	61
Operating Cost of Revenue	90	56	61	61
Total Operating Expenses	259	127	153	137
Selling, General & Admin Expense	157	88	102	99
Research & Development Expense	62	26	37	38
Restructuring Charge	40	14	14	-
Total Other Income / (Expense), net	37	2.40	-77	3.80
Interest Expense	3.32	4.57	4.33	3.82
Interest & Investment Income	20	5.57	2.23	0.00
Other Income / (Expense), net	20	1.39	-75	7.62
Income Tax Expense	0.57	0.45	-2.83	-4.42
Preferred Stock Dividends Declared	46	0.00	0.00	-
Basic Earnings per Share	($0.52)	($0.94)	($2.43)	($0.78)
Weighted Average Basic Shares Outstanding	353.25M	79.16M	78.31M	75.79M
Diluted Earnings per Share	($0.52)	($0.94)	($2.43)	($0.78)
Weighted Average Diluted Shares Outstanding	353.25M	79.16M	78.31M	75.79M
Weighted Average Basic & Diluted Shares Outstanding	378.99M	290.12M	79.06M	77.20M

This table shows Standard BioTools' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	9/30/2024	6/30/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-27	-46	-20	-21	-17	-17	-21	-29
Consolidated Net Income / (Loss)	-27	-46	-20	-21	-17	-17	-21	-29
Net Income / (Loss) Continuing Operations	-27	-46	-20	-21	-17	-17	-21	-29
Total Pre-Tax Income	-27	-46	-20	-21	-17	-17	-21	-30
Total Operating Income	-32	-51	-21	-21	-17	-17	-21	-29
Total Gross Profit	23	15	13	11	14	12	11	9.22
Total Revenue	45	37	28	25	28	25	27	26
Operating Revenue	45	37	28	25	28	25	27	26
Total Cost of Revenue	22	22	15	14	14	13	16	16
Operating Cost of Revenue	22	22	15	14	14	13	16	16
Total Operating Expenses	55	65	35	32	31	29	32	38
Selling, General & Admin Expense	34	38	21	22	23	21	15	26
Research & Development Expense	13	19	6.97	6.37	6.18	6.43	7.43	8.49
Restructuring Charge	7.42	8.53	6.48	3.66	2.27	1.15	-	3.42
Total Other Income / (Expense), net	4.90	4.86	1.45	0.23	0.71	0.01	0.34	-1.11
Interest & Investment Income	3.94	4.44	4.92	0.34	0.24	0.07	62	0.00
Other Income / (Expense), net	0.96	0.41	1.10	-0.12	0.47	-0.06	-61	-0.06
Income Tax Expense	0.12	0.06	-0.16	0.05	0.30	0.26	0.07	-0.71
Preferred Stock Dividends Declared	0.00	0.00	-	0.00	0.00	0.00	-	-
Basic Earnings per Share	($0.07)	($0.12)	($0.24)	($0.27)	($0.22)	($0.21)	($0.25)	($0.37)
Weighted Average Basic Shares Outstanding	371.54M	372.33M	79.16M	79.15M	78.67M	79.08M	78.31M	78.90M
Diluted Earnings per Share	($0.07)	($0.12)	($0.24)	($0.27)	($0.22)	($0.21)	($0.25)	($0.37)
Weighted Average Diluted Shares Outstanding	371.54M	372.33M	79.16M	79.15M	78.67M	79.08M	78.31M	78.90M
Weighted Average Basic & Diluted Shares Outstanding	372.26M	371.15M	290.12M	79.40M	78.96M	78.38M	79.06M	79.30M

This table details how cash moves in and out of Standard BioTools' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021
Net Change in Cash & Equivalents	116	-30	53	-40
Net Cash From Operating Activities	-143	-43	-89	-44
Net Cash From Continuing Operating Activities	-143	-43	-89	-44
Net Income / (Loss) Continuing Operations	-139	-75	-190	-59
Consolidated Net Income / (Loss)	-139	-75	-190	-59
Depreciation Expense	13	3.98	3.50	3.65
Amortization Expense	-3.09	9.94	11	13
Non-Cash Adjustments To Reconcile Net Income	8.31	15	101	18
Changes in Operating Assets and Liabilities, net	-22	2.73	-14	-19
Net Cash From Investing Activities	363	20	-88	-12
Net Cash From Continuing Investing Activities	363	20	-88	-12
Purchase of Property, Plant & Equipment	-8.36	-2.83	-3.83	-13
Acquisitions	-1.39	0.00	0.00	-
Purchase of Investments	-256	-95	-137	0.00
Sale and/or Maturity of Investments	349	118	53	0.00
Other Investing Activities, net	280	0.00	0.00	1.32
Net Cash From Financing Activities	-103	-6.81	231	16
Net Cash From Continuing Financing Activities	-103	-6.81	231	16
Repayment of Debt	-64	-2.08	-6.84	-0.50
Repurchase of Common Equity	-40	-5.41	-13	-0.08
Issuance of Debt	0.00	0.00	25	17
Issuance of Preferred Equity	0.00	0.00	225	0.00
Issuance of Common Equity	0.92	0.72	0.82	1.49
Other Financing Activities, net	0.69	-0.04	-0.11	-1.79
Effect of Exchange Rate Changes	-0.79	0.03	-0.40	-0.02
Cash Interest Paid	3.09	3.82	3.49	3.15
Cash Income Taxes Paid	0.61	0.80	0.31	2.09

This table details how cash moves in and out of Standard BioTools' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-43	-59	-28	-63	29	32	21	-14
Net Cash From Operating Activities	-14	-28	-14	-11	-9.33	-8.49	-19	-25
Net Cash From Continuing Operating Activities	-14	-28	-14	-11	-9.33	-8.49	-19	-25
Net Income / (Loss) Continuing Operations	-34	-27	-20	-21	-17	-17	-21	-29
Consolidated Net Income / (Loss)	-34	-27	-20	-21	-17	-17	-21	-29
Depreciation Expense	3.14	3.15	1.11	1.19	0.83	0.86	0.82	0.80
Amortization Expense	-0.32	-1.05	1.86	2.63	2.81	2.64	1.50	3.01
Non-Cash Adjustments To Reconcile Net Income	3.40	10	1.23	6.60	3.36	3.54	2.76	7.14
Changes in Operating Assets and Liabilities, net	14	-13	1.52	-0.83	0.71	1.32	-3.42	-6.13
Net Cash From Investing Activities	26	-31	-13	-50	40	43	40	11
Net Cash From Continuing Investing Activities	26	-31	-13	-50	40	43	40	11
Purchase of Property, Plant & Equipment	-3.38	-2.26	-0.08	-0.91	-0.84	-1.01	-0.76	-1.26
Purchase of Investments	-30	-79	-39	-49	-	-6.84	-	-
Sale and/or Maturity of Investments	60	50	26	-	41	51	41	12
Net Cash From Financing Activities	-55	-0.00	-1.00	-1.16	-2.08	-2.56	-0.27	-0.01
Net Cash From Continuing Financing Activities	-55	-0.00	-1.00	-1.16	-2.08	-2.56	-0.27	-0.01
Repayment of Debt	-55	-	-1.25	-0.83	-	0.00	-	-
Issuance of Common Equity	0.49	-	0.40	-	-	-	0.32	-
Other Financing Activities, net	-0.01	-0.00	0.02	0.07	-0.04	-0.09	-0.03	-0.01
Effect of Exchange Rate Changes	-0.27	-0.41	0.23	-0.15	-0.07	0.02	0.32	-0.28
Cash Interest Paid	1.44	0.00	1.65	0.25	1.69	0.23	1.65	0.17
Cash Income Taxes Paid	0.20	0.06	0.17	0.12	0.21	0.31	0.06	-0.39

This table presents Standard BioTools' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021
Total Assets	612	323	390	275
Total Current Assets	376	158	209	72
Cash & Equivalents	167	52	81	28
Short-Term Investments	126	63	84	0.00
Accounts Receivable	34	20	17	18
Inventories, net	41	21	21	21
Prepaid Expenses	8.66	3.13	4.28	4.47
Plant, Property, & Equipment, net	43	24	26	28
Total Noncurrent Assets	194	141	156	175
Goodwill	111	106	106	106
Intangible Assets	29	1.40	13	28
Other Noncurrent Operating Assets	54	33	37	41
Total Liabilities & Shareholders' Equity	612	323	390	275
Total Liabilities	141	160	161	181
Total Current Liabilities	66	109	43	50
Short-Term Debt	0.00	60	2.08	6.84
Accounts Payable	12	9.24	7.91	11
Accrued Expenses	31	21	6.18	8.67
Current Deferred Revenue	17	15	14	15
Other Current Liabilities	6.23	4.32	3.68	3.05
Total Noncurrent Liabilities	75	51	117	131
Long-Term Debt	0.30	3.98	63	64
Noncurrent Deferred Revenue	33	3.52	3.82	5.97
Noncurrent Deferred & Payable Income Tax Liabilities	1.08	0.84	1.06	4.33
Other Noncurrent Operating Liabilities	41	42	49	57
Commitments & Contingencies	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	0.00	311	311	0.00
Total Equity & Noncontrolling Interests	472	-148	-81	95
Total Preferred & Common Equity	472	-148	-81	95
Preferred Stock	0.00	0.00	0.00	0.00
Total Common Equity	472	-148	-81	95
Common Stock	1,703	861	847	832
Retained Earnings	-1,186	-1,001	-926	-736
Treasury Stock	-46	-5.98	-0.56	0.00
Accumulated Other Comprehensive Income / (Loss)	1.23	-2.22	-1.90	-0.91

This table presents Standard BioTools' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	682	709	339	356	372	415
Total Current Assets	454	480	171	183	195	229
Cash & Equivalents	211	270	80	142	114	60
Short-Term Investments	156	125	49	0.00	41	125
Accounts Receivable	35	32	17	15	15	17
Inventories, net	43	43	22	22	23	22
Prepaid Expenses	9.32	10	3.40	3.57	3.37	4.61
Plant, Property, & Equipment, net	42	43	25	25	25	27
Total Noncurrent Assets	186	186	144	148	152	159
Goodwill	106	106	106	106	106	106
Intangible Assets	23	24	4.20	7.00	9.80	15
Other Noncurrent Operating Assets	56	56	34	35	36	38
Total Liabilities & Shareholders' Equity	682	709	339	356	372	415
Total Liabilities	192	198	160	158	158	166
Total Current Liabilities	121	124	52	47	44	46
Short-Term Debt	55	55	5.00	4.58	3.33	0.83
Accounts Payable	11	13	7.33	6.09	6.11	9.31
Accrued Expenses	32	32	10	7.18	6.88	6.91
Current Deferred Revenue	17	19	15	15	15	15
Other Current Liabilities	6.12	5.85	3.98	3.91	3.76	3.52
Total Noncurrent Liabilities	72	75	108	111	114	120
Long-Term Debt	0.30	0.30	60	61	62	64
Noncurrent Deferred Revenue	33	33	3.47	3.79	3.83	4.43
Noncurrent Deferred & Payable Income Tax Liabilities	0.84	0.84	1.02	1.05	1.05	0.62
Other Noncurrent Operating Liabilities	38	40	44	46	47	51
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	0.00	0.00	311	311	311	311
Total Equity & Noncontrolling Interests	489	510	-132	-113	-97	-63
Total Preferred & Common Equity	489	510	-132	-113	-97	-63
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	489	510	-132	-113	-97	-63
Common Stock	1,689	1,683	857	854	850	845
Retained Earnings	-1,152	-1,125	-981	-960	-943	-905
Treasury Stock	-46	-46	-5.80	-5.40	-3.03	-
Accumulated Other Comprehensive Income / (Loss)	-1.41	-1.50	-1.95	-1.55	-1.33	-2.61

This table displays calculated financial ratios and metrics derived from Standard BioTools' official financial filings.

Metric	2024	2023	2022	2021
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021
Growth Metrics	-	-	-	-
Revenue Growth	64.03%	8.57%	-24.99%	-5.47%
EBITDA Growth	-137.83%	65.27%	-304.36%	-36.20%
EBIT Growth	-106.35%	60.59%	-218.90%	-18.42%
NOPAT Growth	-128.77%	34.08%	-72.26%	-32.18%
Net Income Growth	-86.03%	60.73%	-220.91%	-11.73%
EPS Growth	44.68%	61.32%	-211.54%	-5.41%
Operating Cash Flow Growth	-231.40%	51.56%	-102.83%	-185.79%
Free Cash Flow Firm Growth	-419.87%	49.97%	-22.44%	-410.55%
Invested Capital Growth	60.21%	-13.25%	-6.05%	9.97%
Revenue Q/Q Growth	0.00%	1.11%	-10.30%	-4.63%
EBITDA Q/Q Growth	0.00%	-2.61%	-73.03%	13.42%
EBIT Q/Q Growth	0.00%	-0.94%	-61.57%	10.44%
NOPAT Q/Q Growth	0.00%	-0.36%	-9.26%	7.72%
Net Income Q/Q Growth	0.00%	1.41%	-6.39%	12.67%
EPS Q/Q Growth	0.00%	1.05%	-5.65%	14.29%
Operating Cash Flow Q/Q Growth	0.00%	10.58%	-15.78%	-8.01%
Free Cash Flow Firm Q/Q Growth	0.00%	10.09%	-6.74%	-15.85%
Invested Capital Q/Q Growth	0.00%	-3.00%	0.65%	2.33%
Profitability Metrics	-	-	-	-
Gross Margin	48.31%	47.44%	37.83%	53.13%
EBITDA Margin	-83.57%	-57.64%	-180.17%	-33.42%
Operating Margin	-100.46%	-72.03%	-118.64%	-51.66%
EBIT Margin	-88.97%	-70.73%	-194.82%	-45.82%
Profit (Net Income) Margin	-79.62%	-70.21%	-194.08%	-45.36%
Tax Burden Percent	100.41%	100.61%	98.53%	93.05%
Interest Burden Percent	89.12%	98.66%	101.10%	106.39%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-84.32%	-44.55%	-61.14%	-36.05%
ROIC Less NNEP Spread (ROIC-NNEP)	-74.88%	-16.92%	311.97%	-120.97%
Return on Net Nonoperating Assets (RNNOA)	40.57%	6.56%	-56.07%	-14.65%
Return on Equity (ROE)	-43.75%	-37.99%	-117.21%	-50.71%
Cash Return on Invested Capital (CROIC)	-130.59%	-30.36%	-54.90%	-45.55%
Operating Return on Assets (OROA)	-33.18%	-21.09%	-57.35%	-19.95%
Return on Assets (ROA)	-29.70%	-20.93%	-57.13%	-19.75%
Return on Common Equity (ROCE)	-22.30%	22.19%	-4.74%	-50.71%
Return on Equity Simple (ROE_SIMPLE)	-29.44%	50.43%	233.34%	-62.62%
Net Operating Profit after Tax (NOPAT)	-123	-54	-81	-47
NOPAT Margin	-70.32%	-50.42%	-83.05%	-36.16%
Net Nonoperating Expense Percent (NNEP)	-9.43%	-27.63%	-373.11%	84.92%
Return On Investment Capital (ROIC_SIMPLE)	-25.99%	63.43%	490.76%	-
Cost of Revenue to Revenue	51.69%	52.56%	62.17%	46.87%
SG&A Expenses to Revenue	89.78%	82.32%	104.43%	75.73%
R&D to Revenue	35.78%	24.40%	38.17%	29.06%
Operating Expenses to Revenue	148.77%	119.48%	156.47%	104.79%
Earnings before Interest and Taxes (EBIT)	-155	-75	-191	-60
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-146	-61	-176	-44
Valuation Ratios	-	-	-	-
Price to Book Value (P/BV)	1.38	0.00	0.00	3.17
Price to Tangible Book Value (P/TBV)	1.97	0.00	0.00	0.00
Price to Revenue (P/Rev)	3.73	1.65	0.95	2.30
Price to Earnings (P/E)	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.00	3.89	2.35	2.50
Enterprise Value to Revenue (EV/Rev)	2.06	4.09	3.09	2.62
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-
Debt to Equity	0.00	0.39	0.28	0.75
Long-Term Debt to Equity	0.00	0.02	0.27	0.68
Financial Leverage	-0.54	-0.39	-0.18	0.12
Leverage Ratio	1.47	1.82	2.05	2.57
Compound Leverage Factor	1.31	1.79	2.07	2.73
Debt to Total Capital	0.06%	28.01%	22.02%	42.89%
Short-Term Debt to Total Capital	0.00%	26.26%	0.71%	4.13%
Long-Term Debt to Total Capital	0.06%	1.76%	21.31%	38.76%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	137.29%	105.62%	0.00%
Common Equity to Total Capital	99.94%	-65.30%	-27.65%	57.11%
Debt to EBITDA	0.00	-1.04	-0.37	-1.63
Net Debt to EBITDA	2.01	0.84	0.57	-0.98
Long-Term Debt to EBITDA	0.00	-0.07	-0.36	-1.47
Debt to NOPAT	0.00	-1.18	-0.80	-1.50
Net Debt to NOPAT	2.39	0.96	1.24	-0.90
Long-Term Debt to NOPAT	0.00	-0.07	-0.77	-1.36
Altman Z-Score	0.12	-3.94	-3.83	-2.89
Noncontrolling Interest Sharing Ratio	49.02%	158.40%	95.95%	0.00%
Liquidity Ratios	-	-	-	-
Current Ratio	5.70	1.45	4.81	1.45
Quick Ratio	4.95	1.23	4.21	0.94
Cash Flow Metrics	-	-	-	-
Free Cash Flow to Firm (FCFF)	-190	-37	-73	-60
Operating Cash Flow to CapEx	-1,716.98%	-1,529.04%	-2,336.47%	-332.18%
Free Cash Flow to Firm to Interest Expense	-57.30	-8.00	-16.87	-15.61
Operating Cash Flow to Interest Expense	-43.26	-9.48	-20.64	-11.53
Operating Cash Flow Less CapEx to Interest Expense	-45.78	-10.10	-21.52	-14.99
Efficiency Ratios	-	-	-	-
Asset Turnover	0.37	0.30	0.29	0.44
Accounts Receivable Turnover	6.55	5.76	5.50	5.97
Inventory Turnover	2.94	2.66	2.88	3.02
Fixed Asset Turnover	5.23	4.27	3.65	5.73
Accounts Payable Turnover	8.38	6.52	6.58	6.18
Days Sales Outstanding (DSO)	55.73	63.40	66.33	61.14
Days Inventory Outstanding (DIO)	124.01	137.16	126.76	120.80
Days Payable Outstanding (DPO)	43.55	56.00	55.49	59.10
Cash Conversion Cycle (CCC)	136.19	144.56	137.60	122.83
Capital & Investment Metrics	-	-	-	-
Invested Capital	179	112	129	137
Invested Capital Turnover	1.20	0.88	0.74	1.00
Increase / (Decrease) in Invested Capital	67	-17	-8.30	12
Enterprise Value (EV)	359	435	303	342
Market Capitalization	651	175	93	300
Book Value per Share	$1.27	($1.86)	($1.03)	$1.24
Tangible Book Value per Share	$0.89	($3.22)	($2.53)	($0.52)
Total Capital	472	227	295	166
Total Debt	0.30	64	65	71
Total Long-Term Debt	0.30	3.98	63	64
Net Debt	-293	-51	-101	43
Capital Expenditures (CapEx)	8.36	2.83	3.83	13
Debt-free, Cash-free Net Working Capital (DFCFNWC)	17	-6.48	1.67	0.89
Debt-free Net Working Capital (DFNWC)	310	108	167	29
Net Working Capital (NWC)	310	49	165	22
Net Nonoperating Expense (NNE)	16	21	109	12
Net Nonoperating Obligations (NNO)	-293	-51	-101	43
Total Depreciation and Amortization (D&A)	9.43	14	14	16
Debt-free, Cash-free Net Working Capital to Revenue	9.81%	-6.09%	1.71%	0.68%
Debt-free Net Working Capital to Revenue	177.71%	101.95%	170.96%	22.47%
Net Working Capital to Revenue	177.71%	45.97%	168.84%	17.23%
Earnings Adjustments	-	-	-	-
Adjusted Basic Earnings per Share	($0.52)	($0.94)	($2.43)	($0.78)
Adjusted Weighted Average Basic Shares Outstanding	353.25M	79.16M	78.31M	75.79M
Adjusted Diluted Earnings per Share	($0.52)	($0.94)	($2.43)	($0.78)
Adjusted Weighted Average Diluted Shares Outstanding	353.25M	79.16M	78.31M	75.79M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	378.99M	290.12M	79.06M	77.20M
Normalized Net Operating Profit after Tax (NOPAT)	-94	-44	-72	-47
Normalized NOPAT Margin	-54.08%	-41.50%	-73.34%	-36.16%
Pre Tax Income Margin	-79.29%	-69.78%	-196.97%	-48.75%
Debt Service Ratios	-	-	-	-
EBIT to Interest Expense	-46.80	-16.47	-44.06	-15.65
NOPAT to Interest Expense	-36.99	-11.74	-18.78	-12.35
EBIT Less CapEx to Interest Expense	-49.32	-17.09	-44.94	-19.12
NOPAT Less CapEx to Interest Expense	-39.51	-12.36	-19.66	-15.82
Payout Ratios	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-29.15%	-7.25%	-6.90%	-0.13%

This table displays calculated financial ratios and metrics derived from Standard BioTools' official financial filings.

Metric	Q3 2024	Q2 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	9/30/2024	6/30/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-
Revenue Growth	77.27%	34.48%	4.32%	-1.09%	47.34%	-5.23%	-29.38%	-10.03%
EBITDA Growth	-64.05%	-275.53%	78.23%	30.90%	64.66%	61.15%	-1,463.05%	-147.65%
EBIT Growth	-44.51%	-195.04%	75.23%	26.82%	59.37%	56.23%	-792.95%	-103.47%
NOPAT Growth	-49.81%	-189.52%	-1.30%	27.06%	54.75%	39.67%	-87.51%	-48.01%
Net Income Growth	-28.29%	-168.30%	5.13%	28.64%	73.18%	77.92%	-121.05%	-112.57%
EPS Growth	74.07%	45.45%	4.00%	27.03%	73.17%	78.79%	-108.33%	-105.56%
Operating Cash Flow Growth	-144.21%	0.00%	26.69%	53.63%	68.89%	45.57%	-173.94%	-159.23%
Free Cash Flow Firm Growth	-4,079.08%	-1,346.95%	132.46%	85.76%	72.74%	-382.28%	68.11%	-1.79%
Invested Capital Growth	54.60%	41.24%	-13.25%	-9.98%	-4.98%	35.23%	-6.05%	-4.49%
Revenue Q/Q Growth	20.87%	0.00%	11.12%	-8.31%	10.14%	-7.04%	5.36%	36.58%
EBITDA Q/Q Growth	42.80%	0.00%	0.86%	-30.94%	-1.43%	16.55%	-214.74%	33.03%
EBIT Q/Q Growth	38.61%	0.00%	4.70%	-25.34%	-1.99%	14.98%	-181.51%	30.41%
NOPAT Q/Q Growth	37.22%	0.00%	-1.01%	-21.34%	-5.16%	21.40%	27.27%	24.73%
Net Income Q/Q Growth	41.08%	0.00%	5.82%	-23.22%	-1.17%	19.20%	29.16%	53.69%
EPS Q/Q Growth	41.67%	0.00%	11.11%	-22.73%	-4.76%	16.00%	32.43%	54.88%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	-23.21%	-22.33%	-9.95%	55.76%	22.06%	17.93%
Free Cash Flow Firm Q/Q Growth	0.05%	0.00%	203.26%	65.39%	86.65%	-580.25%	54.69%	33.78%
Invested Capital Q/Q Growth	4.45%	0.00%	-3.00%	-4.58%	-3.07%	-3.31%	0.65%	0.73%
Profitability Metrics	-	-	-	-	-	-	-	-
Gross Margin	51.73%	40.07%	47.58%	43.97%	49.17%	48.89%	41.33%	35.95%
EBITDA Margin	-63.74%	-134.68%	-61.45%	-68.87%	-48.23%	-52.37%	-294.49%	-98.58%
Operating Margin	-70.53%	-135.79%	-75.87%	-83.46%	-63.07%	-66.06%	-78.13%	-113.18%
EBIT Margin	-68.40%	-134.68%	-71.97%	-83.92%	-61.39%	-66.29%	-303.07%	-113.43%
Profit (Net Income) Margin	-59.90%	-122.88%	-70.16%	-82.77%	-61.59%	-67.05%	-77.14%	-114.74%
Tax Burden Percent	100.44%	100.12%	99.19%	100.24%	101.80%	101.59%	100.34%	97.63%
Interest Burden Percent	87.19%	91.13%	98.28%	98.40%	98.56%	99.57%	25.37%	103.61%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	-46.92%	-50.50%	-37.55%	-41.19%	-40.27%	-66.01%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	-40.61%	-43.82%	-33.24%	12.65%	-19.45%	-44.76%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	15.74%	18.91%	15.77%	-1.04%	3.50%	11.03%
Return on Equity (ROE)	0.00%	0.00%	-31.19%	-31.60%	-21.79%	-42.23%	-36.77%	-54.98%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-30.36%	-33.41%	-42.43%	-97.95%	-54.90%	-52.21%
Operating Return on Assets (OROA)	0.00%	0.00%	-21.46%	-23.40%	-16.25%	-19.89%	-89.21%	-35.53%
Return on Assets (ROA)	0.00%	0.00%	-20.92%	-23.09%	-16.30%	-20.12%	-22.71%	-35.94%
Return on Common Equity (ROCE)	0.00%	0.00%	18.21%	14.36%	6.97%	13.42%	-1.49%	-5.78%
Return on Equity Simple (ROE_SIMPLE)	0.00%	0.00%	0.00%	57.49%	74.22%	134.48%	0.00%	284.77%
Net Operating Profit after Tax (NOPAT)	-22	-35	-15	-15	-12	-12	-15	-20
NOPAT Margin	-49.37%	-95.05%	-53.11%	-58.42%	-44.15%	-46.24%	-54.69%	-79.23%
Net Nonoperating Expense Percent (NNEP)	-2.52%	-4.97%	-6.31%	-6.69%	-4.31%	-53.84%	-20.81%	-21.25%
Cost of Revenue to Revenue	48.27%	59.93%	52.42%	56.03%	50.84%	51.11%	58.67%	64.05%
SG&A Expenses to Revenue	76.50%	101.26%	75.76%	87.88%	81.69%	84.78%	55.46%	102.71%
R&D to Revenue	29.26%	51.67%	24.71%	25.11%	22.35%	25.59%	27.48%	33.09%
Operating Expenses to Revenue	122.26%	175.86%	123.45%	127.43%	112.24%	114.95%	119.46%	149.13%
Earnings before Interest and Taxes (EBIT)	-31	-50	-20	-21	-17	-17	-82	-29
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-29	-50	-17	-17	-13	-13	-80	-25
Valuation Ratios	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.46	1.29	0.00	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	1.99	1.73	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.00	0.00	1.65	2.18	1.43	1.60	0.95	0.79
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.27	1.87	3.89	4.13	3.19	3.02	2.35	2.17
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	4.09	4.53	3.66	3.89	3.09	2.54
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-
Debt to Equity	0.11	0.11	0.39	0.36	0.33	0.30	0.28	0.26
Long-Term Debt to Equity	0.00	0.00	0.02	0.33	0.31	0.29	0.27	0.26
Financial Leverage	-0.56	-0.59	-0.39	-0.43	-0.47	-0.08	-0.18	-0.25
Leverage Ratio	1.53	1.50	1.82	1.76	1.69	2.72	2.05	2.00
Compound Leverage Factor	1.33	1.37	1.78	1.73	1.67	2.71	0.52	2.08
Debt to Total Capital	10.14%	9.74%	28.01%	26.46%	24.80%	23.31%	22.02%	20.66%
Short-Term Debt to Total Capital	10.08%	9.69%	26.26%	2.05%	1.74%	1.19%	0.71%	0.27%
Long-Term Debt to Total Capital	0.05%	0.05%	1.76%	24.41%	23.06%	22.11%	21.31%	20.40%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	137.29%	127.50%	118.30%	111.49%	105.62%	99.37%
Common Equity to Total Capital	89.86%	90.26%	-65.30%	-53.96%	-43.09%	-34.80%	-27.65%	-20.03%
Debt to EBITDA	0.00	0.00	-1.04	-1.08	-0.97	-0.71	-0.37	-0.63
Net Debt to EBITDA	0.00	0.00	0.84	1.08	1.14	0.97	0.57	1.18
Long-Term Debt to EBITDA	0.00	0.00	-0.07	-1.00	-0.90	-0.67	-0.36	-0.63
Debt to NOPAT	0.00	0.00	-1.18	-1.21	-1.11	-0.88	-0.80	-0.87
Net Debt to NOPAT	0.00	0.00	0.96	1.20	1.31	1.21	1.24	1.62
Long-Term Debt to NOPAT	0.00	0.00	-0.07	-1.12	-1.03	-0.84	-0.77	-0.86
Altman Z-Score	0.00	0.00	-3.37	-2.66	-2.60	-2.36	-2.91	-2.18
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	158.40%	145.43%	131.98%	131.77%	95.95%	89.48%
Liquidity Ratios	-	-	-	-	-	-	-	-
Current Ratio	3.76	3.88	1.45	3.30	3.91	4.45	4.81	4.96
Quick Ratio	3.33	3.45	1.23	2.81	3.36	3.86	4.21	4.39
Cash Flow Metrics	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-85	-85	2.10	-2.04	-5.89	-44	-6.48	-14
Operating Cash Flow to CapEx	-1,235.88%	0.00%	-18,026.92%	-1,260.99%	-1,113.25%	-840.10%	-2,540.53%	-1,947.07%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	-5.45	-13.63
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	-16.12	-23.46
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	-16.75	-24.67
Efficiency Ratios	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.30	0.28	0.26	0.30	0.29	0.31
Accounts Receivable Turnover	0.00	0.00	5.76	6.21	8.09	6.45	5.50	7.04
Inventory Turnover	0.00	0.00	2.66	2.60	2.64	2.60	2.88	2.72
Fixed Asset Turnover	0.00	0.00	4.27	4.11	4.07	3.66	3.65	3.94
Accounts Payable Turnover	0.00	0.00	6.52	6.85	7.84	6.39	6.58	6.28
Days Sales Outstanding (DSO)	0.00	0.00	63.40	58.74	45.09	56.56	66.33	51.86
Days Inventory Outstanding (DIO)	0.00	0.00	137.16	140.55	138.37	140.43	126.76	134.40
Days Payable Outstanding (DPO)	0.00	0.00	56.00	53.28	46.58	57.16	55.49	58.14
Cash Conversion Cycle (CCC)	0.00	0.00	144.56	146.01	136.88	139.82	137.60	128.12
Capital & Investment Metrics	-	-	-	-	-	-	-	-
Invested Capital	178	171	112	115	121	125	129	128
Invested Capital Turnover	0.00	0.00	0.88	0.86	0.85	0.89	0.74	0.83
Increase / (Decrease) in Invested Capital	63	50	-17	-13	-6.33	32	-8.30	-6.02
Enterprise Value (EV)	405	319	435	476	385	376	303	277
Market Capitalization	716	659	175	229	151	154	93	87
Book Value per Share	$1.32	$1.37	($1.86)	($1.67)	($1.45)	($1.23)	($1.03)	($0.80)
Tangible Book Value per Share	$0.97	$1.02	($3.22)	($3.07)	($2.89)	($2.70)	($2.53)	($2.34)
Total Capital	545	565	227	244	263	279	295	313
Total Debt	55	55	64	65	65	65	65	65
Total Long-Term Debt	0.30	0.30	3.98	60	61	62	63	64
Net Debt	-311	-340	-51	-64	-77	-89	-101	-120
Capital Expenditures (CapEx)	2.26	0.00	0.08	0.91	0.84	1.01	0.76	1.26
Debt-free, Cash-free Net Working Capital (DFCFNWC)	22	16	-6.48	-4.91	-1.49	-0.06	1.67	-1.49
Debt-free Net Working Capital (DFNWC)	388	411	108	124	141	154	167	184
Net Working Capital (NWC)	333	356	49	119	136	151	165	183
Net Nonoperating Expense (NNE)	4.74	10	4.81	6.18	4.83	5.23	6.07	9.11
Net Nonoperating Obligations (NNO)	-311	-340	-51	-64	-77	-89	-101	-120
Total Depreciation and Amortization (D&A)	2.10	0.00	2.97	3.82	3.64	3.50	2.32	3.81
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	-6.09%	-4.67%	-1.41%	-0.07%	1.71%	-1.36%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	101.95%	117.84%	133.53%	159.97%	170.96%	168.22%
Net Working Capital to Revenue	0.00%	0.00%	45.97%	113.09%	129.19%	156.52%	168.84%	167.46%
Earnings Adjustments	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.07)	($0.12)	($0.24)	($0.27)	($0.22)	($0.21)	($0.25)	($0.37)
Adjusted Weighted Average Basic Shares Outstanding	371.54M	372.33M	79.16M	79.15M	78.67M	79.08M	78.31M	78.90M
Adjusted Diluted Earnings per Share	($0.07)	($0.12)	($0.24)	($0.27)	($0.22)	($0.21)	($0.25)	($0.37)
Adjusted Weighted Average Diluted Shares Outstanding	371.54M	372.33M	79.16M	79.15M	78.67M	79.08M	78.31M	78.90M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	372.26M	371.15M	290.12M	79.40M	78.96M	78.38M	79.06M	79.30M
Normalized Net Operating Profit after Tax (NOPAT)	-17	-29	-10	-12	-11	-11	-15	-18
Normalized NOPAT Margin	-37.82%	-79.00%	-37.02%	-48.31%	-38.41%	-43.04%	-54.69%	-69.89%
Pre Tax Income Margin	-59.64%	-122.73%	-70.73%	-82.58%	-60.50%	-66.01%	-76.88%	-117.52%
Debt Service Ratios	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	-68.82	-27.73
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	-12.42	-19.37
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	-69.45	-28.94
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	-13.05	-20.57
Payout Ratios	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	-7.25%	-7.66%	-6.42%	-11.92%	-6.90%	-7.05%

Frequently Asked Questions About Standard BioTools' Financials

When does Standard BioTools's fiscal year end?

According to the most recent income statement we have on file, Standard BioTools' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Standard BioTools' net income changed over the last 3 years?

Standard BioTools' net income appears to be on an upward trend, with a most recent value of -$138.89 million in 2024, rising from -$59.24 million in 2021. The previous period was -$74.66 million in 2023. See Standard BioTools' forecast for analyst expectations on what’s next for the company.

What is Standard BioTools's operating income?

Standard BioTools's total operating income in 2024 was -$175.24 million, based on the following breakdown:

Total Gross Profit: $84.26 million
Total Operating Expenses: $259.50 million

How has Standard BioTools revenue changed over the last 3 years?

Over the last 3 years, Standard BioTools' total revenue changed from $130.58 million in 2021 to $174.43 million in 2024, a change of 33.6%.

How much debt does Standard BioTools have?

Standard BioTools' total liabilities were at $140.62 million at the end of 2024, a 12.0% decrease from 2023, and a 22.1% decrease since 2021.

How much cash does Standard BioTools have?

In the past 3 years, Standard BioTools' cash and equivalents has ranged from $28.45 million in 2021 to $166.73 million in 2024, and is currently $166.73 million as of their latest financial filing in 2024.

How has Standard BioTools' book value per share changed over the last 3 years?

Over the last 3 years, Standard BioTools' book value per share changed from 1.24 in 2021 to 1.27 in 2024, a change of 2.5%.

Related Companies

This page (NASDAQ:LAB) was last updated on 5/28/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Standard BioTools (LAB) Financials

Frequently Asked Questions About Standard BioTools' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Standard BioTools (LAB) Financials

Annual Income Statements for Standard BioTools

Quarterly Income Statements for Standard BioTools

Annual Cash Flow Statements for Standard BioTools

Quarterly Cash Flow Statements for Standard BioTools

Annual Balance Sheets for Standard BioTools

Quarterly Balance Sheets for Standard BioTools

Annual Metrics And Ratios for Standard BioTools

Quarterly Metrics And Ratios for Standard BioTools

Frequently Asked Questions About Standard BioTools' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools